PAM
CAPR icon

PVG Asset Management’s Capricor Therapeutics CAPR Stock Holding History

PVG Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,562
Closed -$90.6K – 99
2025
Q3 		$90.6K Buy
+12,562
New +$92.5K 0.33% 65

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVG Asset Management's CAPR Position: Q4 2025 in Review

PVG Asset Management sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 12,562 shares — an estimated $90.6K sold.

PVG Asset Management first reported a position in CAPR in Q3 2025 and held it in 1 quarter. The position peaked at $90.6K in Q3 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • PVG Asset Management reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PVG Asset Management sold 12,562 Capricor Therapeutics shares in Q4 2025, an estimated $90.6K.
  • PVG Asset Management first reported a position in Capricor Therapeutics in Q3 2025 and held it in 1 quarter.
  • PVG Asset Management's Capricor Therapeutics position peaked at $90.6K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on PVG Asset Management's 13F filing for Q4 2025, filed 30 Jan 2026.